ENGN

Conviction 20HealthcareScan · Thu, Jun 25, 2026

ENGN$1.78+1.71%

ResistanceSupportVol 14

Vol MA14 1.04M

Mar 26Apr 14May 1May 19Jun 8Jun 25

enGene Therapeutics Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.engene.com ↗

Price1.78

Change+1.71%

Gap+0.57%

Rel volume2.24×

Avg volume989.17K

Avg $ vol1.71M

SMA 201.71

SMA 503.65

SMA 2007.03

Price vs 50-51.30%

Price vs 200-74.68%

MA stackbearish

50/200 cross—

Supertrenddown · 2.12

RSI (14)36

MACD hist0.17

MACD cross—

Stoch %K / %D81 / 69

ADX (14)35

+DI / −DI20 / 32

RSI divergence—

MACD divergence—

ATR %+10.46%

ADR %5.06%

52w high12.17

52w low1.44

From 52w high-85.37%

Above 52w low+23.61%

New 52w highNo

SqueezeOn · 6d

Bollinger width14.77%

%B0.76

Donchian pos70.00%

Donchian high1.87

Donchian low1.57

AVWAP (52w high)3.26

vs AVWAP high-45.45%

AVWAP (52w low)1.67

vs AVWAP low+6.38%

OBV trendFlat

Chaikin MF (20)-0.12

Today vs 20d2.24×

Avg vol (14d)1.04M

Avg vol (20d)989.17K

Avg $ vol (20d)1.71M

Market cap119.24M

RS 3m (vs SPY)-86.89%

RS 6m (vs SPY)-87.60%

RS line new highNo

Trend template0/8

Technical rank17.6

1 week+2.30%

1 month+1.14%

3 months-74.82%

6 months-79.70%

1 year-40.47%

YTD-79.89%

P/E-1.02

P/B0.47

P/S—

P/FCF-1.18

EPS2.29

Div yield—

ROE-45.97%

ROA-38.14%

Debt/Eq—

Current12.57

EV/EBITDA-0.73

Gross margin—

Net margin—

Rev growth—

EPS growth-112.73%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value89.41M

Revenue—

Net income-30.23M

Gross profit—

Free cash flow-100.72M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out—

Employees82

ListedWed, Nov 1, 2023

Free float50.18M

Float %74.9%

Short interest1.62M

Days to cover1.1d

Short volume20.4%

Squeeze score27 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction20 / 100

Pattern quality—

Tech rank17.6 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance5.44

Support1.45

Days since event—

Candle confirm—

News sentiment—

Financials as of Thu, Apr 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ENGN

All disclosures →

No recent disclosed trades by Congress in ENGN. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ENGN · 2 buys

Insider	Side	Shares	Value	Traded	Filed
Astley-Sparke Philip Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31K	—	2026-06-16	2026-06-17
BRUNK GERALD A Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31K	—	2026-06-16	2026-06-17

SEC filings

EDGAR filings in ENGN · 4 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.